494 related articles for article (PubMed ID: 27412393)
21. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.
Shechter-Maor G; Bruchim I; Ben-Harim Z; Altaras M; Fishman A
Int J Gynecol Cancer; 2009 May; 19(4):662-4. PubMed ID: 19509567
[TBL] [Abstract][Full Text] [Related]
22. A multi-institutional analysis of sequential versus 'sandwich' adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma.
Onal C; Sari SY; Yildirim BA; Yavas G; Gultekin M; Guler OC; Akyurek S; Yildiz F
J Gynecol Oncol; 2019 May; 30(3):e28. PubMed ID: 30887753
[TBL] [Abstract][Full Text] [Related]
23. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
[TBL] [Abstract][Full Text] [Related]
24. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer.
Hathout L; Wang Y; Wang Q; Vergalasova I; Elshaikh MA; Dimitrova I; Damast S; Li JY; Fields EC; Beriwal S; Keller A; Kidd EA; Usoz M; Jolly S; Jaworski E; Leung EW; Donovan E; Taunk NK; Chino J; Natesan D; Russo AL; Lea JS; Albuquerque KV; Lee LJ
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1423-1431. PubMed ID: 33677053
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
[TBL] [Abstract][Full Text] [Related]
26. Undifferentiated Endometrial Carcinomas: Clinicopathologic Characteristics and Treatment Outcomes.
Ganju RG; Tawfik O; Brown L; Chen AM; Jewell A; TenNapel M; Hoover A
Int J Gynecol Cancer; 2018 Sep; 28(7):1271-1277. PubMed ID: 30036218
[TBL] [Abstract][Full Text] [Related]
27. Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy.
Mundt AJ; McBride R; Rotmensch J; Waggoner SE; Yamada SD; Connell PP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1145-53. PubMed ID: 11483323
[TBL] [Abstract][Full Text] [Related]
28. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel.
Vaidya AP; Littell R; Krasner C; Duska LR
Int J Gynecol Cancer; 2006; 16 Suppl 1():267-72. PubMed ID: 16515602
[TBL] [Abstract][Full Text] [Related]
29. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
Klopp AH; Jhingran A; Ramondetta L; Lu K; Gershenson DM; Eifel PJ
Gynecol Oncol; 2009 Oct; 115(1):6-11. PubMed ID: 19632709
[TBL] [Abstract][Full Text] [Related]
30. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.
Sovak MA; Hensley ML; Dupont J; Ishill N; Alektiar KM; Abu-Rustum N; Barakat R; Chi DS; Sabbatini P; Spriggs DR; Aghajanian C
Gynecol Oncol; 2006 Nov; 103(2):451-7. PubMed ID: 16677690
[TBL] [Abstract][Full Text] [Related]
32. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
[TBL] [Abstract][Full Text] [Related]
33. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
[TBL] [Abstract][Full Text] [Related]
34. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.
Viswanathan AN; Moughan J; Miller BE; Xiao Y; Jhingran A; Portelance L; Bosch WR; Matulonis UA; Horowitz NS; Mannel RS; Souhami L; Erickson BA; Winter KA; Small W; Gaffney DK
Cancer; 2015 Jul; 121(13):2156-63. PubMed ID: 25847373
[TBL] [Abstract][Full Text] [Related]
35. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant chemotherapy with external beamradiation therapy for high-grade, node-positive endometrial cancer.
Lee LJ; Bu P; Feltmate C; Viswanathan AN
Int J Gynecol Cancer; 2014 Oct; 24(8):1441-8. PubMed ID: 25207463
[TBL] [Abstract][Full Text] [Related]
37. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
38. Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions?
Marnitz S; Köhler C; Gharbi N; Kunze S; Jablonska K; Herter J
Strahlenther Onkol; 2018 Nov; 194(11):965-974. PubMed ID: 30112692
[TBL] [Abstract][Full Text] [Related]
39. Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma.
Sozen H; Çiftçi R; Vatansever D; Topuz S; Iyibozkurt AC; Bozbey HU; Yaşa C; Çali H; Yavuz E; Kucucuk S; Aydiner A; Salihoglu Y
Aust N Z J Obstet Gynaecol; 2016 Apr; 56(2):199-206. PubMed ID: 26890292
[TBL] [Abstract][Full Text] [Related]
40. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
